Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
|
1 min read
Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
|
5 min read
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
|
2 min read
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
|
4 min read
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
|
3 min read
New funding will support clinical development of two novel therapies to address complications of cystic fibrosis
|
3 min read
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.
|
5 min read
Foundation welcomes new members to advance its mission
|
7 min read